TrialSpark company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series C | Alive

Total Raised




Last Raised

$156M | 9 mos ago

Mosaic Score

+20 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About TrialSpark

TrialSpark is a clinical trial management software and drug development company. The company aims to accelerate the pace of clinical trials and bring down costs with a software platform that helps sites like hospitals manage trials and collect and analyze data. Per the company, it uses data from social media to find doctors and patients to participate.While it began as a clinical trial technology platform, in 2021, it signaled a move to using its technology for drug development through the acquisition of biologic and small-molecule drugs. TrialSpark began primarily as a technology company that aims to bring treatments to patients faster using technology that improves clinical trials and drug development. TrialSpark has scaled a network of trial sites by partnering with doctors to create clinical trial sites within their existing practices. TrialSpark runs trials out of these doctor practices using a roaming cohort of certified research coordinators, optimized by software, data, and technology. Without variability in operations at the trial site level, TrialSpark cuts out the manual, time-intensive, and costly tasks that delay clinical trial timelines. By creating trial sites with doctors, TrialSpark unlocks the 98 percent of patients who have never been exposed to trials, boosting recruitment and enrollment rates and democratizing access.

TrialSpark Headquarter Location

16 E 34th Street Floor 10

New York, New York, 10016,

United States


ESPs containing TrialSpark

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare / Biopharmaceuticals

These companies provide software that helps track and optimize site operations, processes, and data. Pharma companies, clinical research organizations (CROs), and trial administrators use these solutions to adhere to regulations while streamlining workflows.

TrialSpark named as Leader among 10 other companies, including Florence Healthcare, Clinical Research IO, and 4G Clinical.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing TrialSpark

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TrialSpark is included in 5 Expert Collections, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

1,163 items


Clinical Trials Tech

326 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.


Digital Health

12,999 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Clinical Trials Tech Market Map

108 items

This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.


Biopharma Tech

326 items

Latest TrialSpark News

08:00 ET TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from ...

Jan 10, 2022

-High Line Bio will focus on addressing osteoarthritis, a disease affecting more than 230 million patients worldwide and with no disease modifying therapies -High Line Bio will leverage TrialSpark's unique ability to develop treatments faster and more efficiently for patients than traditional pharma companies through its proprietary technology-enabled clinical trial engine -TrialSpark is continuing to rapidly advance its strategy of acquiring, in-licensing, and investing in clinical-stage assets to develop in-house or in partnership with biotech and pharma companies News provided by Share this article Share this article NEW YORK, Jan. 10, 2022 /PRNewswire/ -- TrialSpark announced today the formation of High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA, Darmstadt, Germany. Sprifermin is a potential first-in-class disease modifying anti-FGF 18 monoclonal antibody that is being evaluated as a potential treatment for osteoarthritis (OA) by promoting cartilage growth. Cartilage loss is an important component in the development of OA, a degenerative joint disease which is one of the biggest unmet medical needs among musculoskeletal conditions. There are no approved disease modifying therapies for OA which is a major cause of disability and impaired quality of life affecting more than 230 million patients globally. As the first monoclonal antibody to demonstrate cartilage growth in a controlled clinical study, Sprifermin is on the forefront of next generation regenerative medicine with the potential to modify the underlying disease pathology in OA. To date, Merck KGaA, Darmstadt, Germany has completed three clinical trials in over 800 patients, including the 549-patients Phase 2 FORWARD trial . TrialSpark will be fully responsible for future development and commercialization of sprifermin. As part of the agreement Merck KGaA, Darmstadt, Germany will receive an upfront payment as well as equity in High Line Bio, and is eligible for clinical and commercial milestone payments in addition to royalties on future net sales. Full financial terms were not disclosed. Sprifermin promotes cartilage growth, and could be a potential disease modifying treatment for osteoarthritis. "We believe sprifermin has the potential to be the first disease modifying therapy approved for the millions of patients suffering from OA," said Gavin Corcoran, Chief Medical Officer at TrialSpark. "Despite recent advances in our understanding of the pathogenesis of OA, clinical development has remained behind other rheumatic diseases. TrialSpark's proprietary clinical trial engine is uniquely positioned to address historical challenges in OA development including long studies requiring many patients, designing optimal pain endpoints, and identifying key patient subgroups most likely to benefit." TrialSpark's ability to leverage its tech-enabled trial engine to run faster and more efficient drug development enables it to pursue programs in indications - such as OA - that have historically required the longest, most expensive clinical trials. High Line Bio will leverage TrialSpark's proprietary tech-enabled clinical trial engine to develop sprifermin in OA using a data-driven approach to identifying novel biomarkers, endpoints, and patient subgroups most likely to benefit from the therapy. TrialSpark is also partnering with industry leaders such as SomaLogic to leverage precision genomics and proteomics platforms to identify key biomarkers and stratify patients using synovial fluid samples from prior clinical studies using AI and machine-learning approaches. Beyond sprifermin, High Line Bio also plans in-license additional complementary products to build a differentiated pipeline focused on OA and regenerative medicine. This transaction is in line with TrialSpark's strategy of creating new companies across key therapeutic areas like inflammatory and autoimmune disease. To date, TrialSpark has successfully in-licensed multiple assets, deploying capital and supporting programs across a broad range of therapeutic areas including CNS, dermatology, and inflammation as part of its mission to bring new treatments to patients faster and more efficiently. As part of its business development and investments strategy, TrialSpark is using balance sheet capital to acquire or license assets, leveraging its in-house clinical development engine to run trials significantly faster and more efficiently than industry. In addition to conventional asset licensing and acquisition, TrialSpark transactions can also include equity investments in both private and public biopharma companies, strategic collaborations to jointly fund and develop assets, and alternative structures including syndication with other investors. TrialSpark is actively pursuing partnerships with both small biotech and larger pharma companies through flexible and creative collaboration structures, maximizing the potential value of drug candidates for all stakeholders through faster and more efficient clinical development programs. TrialSpark is focused on early to mid-stage clinical assets across a range of therapeutic areas, with a focus on chronic diseases that are treated outside of a hospital setting. About Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany, generated sales of €17.5 billion in 66 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. About TrialSpark TrialSpark is a technology-driven pharma company that runs end-to-end clinical trials, focused on bringing new treatments to patients faster and more efficiently. TrialSpark has built a technology platform that optimizes all aspects of a clinical trial, enabling more efficient trial design, faster trial completion, and higher trial data quality. TrialSpark in-licenses and co-develops drug programs through in-house development, joint ventures, and NewCos. TrialSpark is backed by leading investors such as Sam Altman, Lachy Groom, Michael Moritz, Casdin Capital, Sequoia Capital, Thrive Capital, Dragoneer, Section 32, John Doerr, Spark Capital, Felicis Ventures, Sound Ventures, Arrowmark, and previous investors. Press Inquiries

TrialSpark Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

TrialSpark Rank

  • When was TrialSpark founded?

    TrialSpark was founded in 2014.

  • Where is TrialSpark's headquarters?

    TrialSpark's headquarters is located at 16 E 34th Street, New York.

  • What is TrialSpark's latest funding round?

    TrialSpark's latest funding round is Series C.

  • How much did TrialSpark raise?

    TrialSpark raised a total of $238.3M.

  • Who are the investors of TrialSpark?

    Investors of TrialSpark include Thrive Capital, Sequoia Capital, Dragoneer Investment Group, Felicis, ArrowMark Partners and 11 more.

  • Who are TrialSpark's competitors?

    Competitors of TrialSpark include Curebase and 4 more.

You May Also Like

Castor EDC

Castor EDC specializes in electronic data capture for medical research. It aims to take the clinical trial process which it describes as largely being offline and paper-based and digitizes it via software.

Reify Health Logo
Reify Health

Reify Health provides cloud-based software that accelerates the development of new and life-saving therapies. Reify Health aims to change how clinical trials are run through its StudyTeam and Care Access platforms. StudyTeam delivers a technology platform for optimizing patient recruitment and enrollment. Care Access, which conducts decentralized trials at scale, is a decentralized research organization that aims to bring clinical trial infrastructure directly to patients, healthcare providers, and communities. Reify Health was founded in 2012 and is based in Boston, Massachusetts. Logo

FlaskData is an Israeli tech startup that automates patient compliance in chronic disease clinical trials. The product provides personal and precise reinforcement to help chronic disease patients adhere to the protocol based on clinical evidence from previous and current clinical trials of the treatment. FlaskData technology has 3 parts. Part 1 is a cloud platform that unifies data from researchers, patients and medical IoT to a timeline. Part 2 computes clinical measures and generates real-time alerts and analytics. Part 3 uses statistical learning and AI to reinforce patient compliance to the protocol.

Hawthorne Effect Logo
Hawthorne Effect

Hawthorne Effect uses a technology platform and trained freelance healthcare investigators (dubbed HEROs) to help improve clinical trial data quality by helping to prevent patient withdrawals and improve data collection and patient satisfaction rates.

Medable Logo

Medable is a decentralized clinical trial software company. The company's Software-as-a-Service (SaaS) cloud platform aims to provide a path to secure, HIPAA-compliant healthcare applications for researchers, startups, pharma, payers, and academia. This platform allows for supporting patient engagement clinical applications, storing personal health information, and complying with HIPAA and other regulations. Medable aims to enable patient-generated data to drive clinical research, healthcare delivery, and personalized and predictive medicine.


ObvioHealth develops ClaimIt, a proprietary digital platform that utilizes a 100% online and mobile app interface to execute clinical trials. ClaimIt removes the costly overhead of physical site visits and brings the trial directly to the mobile device of each subject.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.